Acadia (ACAD) Q1 2026 Earnings Transcript

Acadia Pharmaceuticals reported first-quarter total revenue of $268 million, up 11% year over year on an adjusted basis, with DAYBUE sales rising 20% to $101 million and NUPLAZID sales up 6% to $167 million. Management reaffirmed full-year 2026 revenue guidance of $1.22 billion to $1.28 billion and highlighted accelerating catalysts, including remifanserin Phase II data expected in August to October 2026 and trofinetide Japan Phase III results in September to November. The company also ended the quarter with a strong $851 million cash balance, but SG&A rose sharply to $171 million as commercial investment expanded.

Analysis

ACAD’s setup is becoming a classic “two commercial engines + one binary catalyst” story, but the second-order effect is that the company is now de-risking execution while increasing optionality. DAYBUE STIX appears to be doing more than adding convenience: it is converting the installed base from a one-time launch curve into a refresh cycle that can pull back discontinued users and shift the SKU mix toward higher-retention patients. That matters because the incremental patients are coming with low new-acquisition friction, which should support revenue growth without requiring a proportionate increase in marketing intensity over time.

NUPLAZID is the more underappreciated operating lever. The refill delay sounds transient, but the key issue is that ACAD is expanding the addressable prescriber universe before the salesforce productivity is fully visible, so Q2 may still understate the full benefit. If the company can translate referral growth into pull-through through late 2026, the market is likely underestimating the duration of the growth runway; conversely, any indication that referrals are “good but not converting” would quickly expose the fragility of the current multiple.

The real stock inflection remains remifanserin. The market will likely trade the August-October readout not as a single event but as a decision tree on platform value: success de-risks the pipeline and supports a multi-year rerating, while a weak signal would compress the entire growth narrative because the current valuation implicitly assigns meaningful probability to the psychosis franchise expansion. Importantly, the biomarker-confirmed design and higher-dose exposure strategy increase the odds of a cleaner readout, but also raise the bar for what counts as commercially meaningful; a merely positive trial may not be enough to sustain upside.

The contrarian view is that consensus may be over-anchored to headline pipeline optionality and underweight the possibility that commercial beats are already visible in the numbers. If STIX uptake continues to reaccelerate and NUPLAZID’s field-force expansion lands, ACAD can grow into the stock before remifanserin reads out, which reduces the “need” for a home-run trial. That creates a favorable asymmetry for owning the stock into catalyst season, but not for complacency after the data if the effect size is merely adequate rather than clearly registration-enabling.

Key Decisions for Investors

• Go long ACAD into the August-October remifanserin window; use a 6-12 week horizon and size for event risk, with upside driven by platform rerating if the trial is clearly Phase III-enabling.
• Buy ACAD call spreads rather than outright stock ahead of the readout to express convexity while limiting downside if the effect size is only middling or the trial is delayed.
• After Q2 results, add on any weakness if DAYBUE STIX prescription momentum continues and NUPLAZID referrals stay double-digit; the setup supports a higher base rate for FY26 revenue progression.
• If remifanserin data are only modestly positive, fade strength via a short-dated put spread or trim longs on the view that the market will de-rate from ‘platform winner’ to ‘incremental commercial story.’
• Relative-value idea: long ACAD vs short a basket of slower-growth neuro names with less near-term catalyst visibility; ACAD has both operating leverage and a binary pipeline catalyst, which should outperform on a risk-adjusted basis into late 2026.